GlassScriptPhysician profile
Jamal Abdel-Halim
NPI 1518077056
$1,955.53
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,915 · 2020: $40.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $571.84 | 2019-2020 | |
| Eisai INC. | $368.74 | 2019 | |
| Acadia Pharmaceuticals INC | $341.86 | 2019 | |
| Lilly USA, LLC | $163.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $113.00 | 2019 | |
| Amgen INC. | $60.54 | 2019 | |
| Abbott Laboratories | $50.46 | 2019 | |
| Bausch Health US, LLC | $47.37 | 2019 | |
| Ironshore Pharmaceuticals INC. | $46.67 | 2019 | |
| Tris Pharma INC | $42.05 | 2019 | |
| Pfizer INC. | $40.85 | 2019 | |
| Livanova USA, INC. | $33.91 | 2019-2020 | |
| Mdd US Operations, LLC | $24.44 | 2019 | |
| Greenwich Biosciences, INC. | $19.56 | 2019 | |
| Allergan, INC. | $19.08 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $11.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Abdel-Halim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.